Global Coronary Artery Disease Market Analysis 2024 – Estimated Market Size And Key Drivers|Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company

The Coronary Artery Disease Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Coronary Artery Disease Market:
https://www.thebusinessresearchcompany.com/report/coronary-artery-disease-global-market-report

According to The Business Research Company’s Coronary Artery Disease Global Market Report 2024, The coronary artery disease market size has grown rapidly in recent years. It will grow from $26.3 billion in 2023 to $28.97 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to prevalence of coronary artery disease, growth in minimally invasive surgeries, increase in sedentary lifestyles, aging population and cad prevalence, evolution of pharmacological treatments..

The coronary artery disease market size is expected to see rapid growth in the next few years. It will grow to $42.65 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to growing lifestyle factors, focus on telemedicine and remote monitoring, expansion of interventional cardiology procedures, shift towards value-based healthcare models, development of novel drug therapies.. Major trends in the forecast period include development of gene therapies, integration of artificial intelligence in diagnosis, focus on mental health in cad care, rise in home-based healthcare services, adoption of remote cardiac rehabilitation..

The rise in the prevalence of coronary artery disease is expected to propel the growth of the coronary artery disease market over the coming years. Coronary artery disease (CAD) is a medical condition characterized by the narrowing or blockage of the coronary arteries, which supply blood to the heart muscle. Coronary artery disease cases are increasing due to increased changes in diet, stress, lack of exercise, obesity, age, and others. Coronary artery disease is treated with drugs using clopidogrel, ticagrelor, warfarin, and heparin and with procedures such as coronary artery bypass grafting, angioplasty, and stenting. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, in 2021, coronary heart disease, the most prevalent form of heart disease, claimed the lives of 375,476 individuals. Approximately 5% of adults aged 20 and above are affected by coronary artery disease (CAD), translating to about 1 in 20 individuals. Therefore, the rise in the prevalence of coronary artery disease is expected to boost the coronary artery disease market during the forecast period.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12052&type=smp

The coronary artery disease market covered in this report is segmented –

1) By Treatment: Medication, Surgery, Additional Therapy, Other Treatments
2) By Diagnosis: Electrocardiogram, Echocardiogram, Stress Test, Cardiac Catheterization, Heart CT Scan, Other Diagnosis
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Channels
4) By End-User: Hospitals, Specialty Clinics, Other End-Users

Major companies operating in the coronary artery disease market are focusing on developing innovative technologies such as AI-based blood tests. An AI-based blood test refers to a diagnostic test that incorporates artificial intelligence (AI) algorithms in the analysis and interpretation of blood-related data. For instance, in February 2023, Cardio Diagnostics Holdings, a US-based AI-based integrated genetic-epigenetic engine manufacturing company, announced the launch of PrecisionCHD. Its a combined genetic and epigenetic blood test designed for the early identification of coronary heart disease. PrecisionCHD exhibits over 75% sensitivity for the detection of coronary heart disease in both men and women. Utilizing a machine-learning model derived from the analysis of billions of genomic and epigenomic data points, the test incorporates epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers.

The coronary artery disease market report table of contents includes:

1. Executive Summary
2. Coronary Artery Disease Market Characteristics
3. Coronary Artery Disease Market Trends And Strategies
4. Coronary Artery Disease Market analysis

5.Coronary Artery Disease Market Size And Growth
6.Coronary Artery Disease Segmentation
7. Coronary Artery Disease Regional And Country Analysis
.
.
.
27.Coronary Artery Disease Competitive Landscape And Company Profiles
28. Coronary Artery Disease Key Mergers And Acquisitions
29.Coronary Artery Disease  Future Outlook and Potential Analysis

TOP MAJOR PALYERS:

  • Pfizer Inc.
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Bayer AG
  • Novartis AG
  • Sanofi S.A.,
  • Bristol-Myers Squibb Company

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model